Navidea touts early results of RA study

By staff writers

April 25, 2022 -- Radiopharmaceutical developer Navidea Biopharmaceuticals said that interim analysis of an ongoing phase IIB study shows positive results for the company's technetium-99m (Tc-99m) tilmanocept radiopharmaceutical in patients with rheumatoid arthritis (RA).

Preliminary results on the first 11 patients indicate that quantitative Tc99m tilmanocept uptake in the hands and wrists of patients is proportional to the amount of macrophage involvement in an individual RA patient's joint inflammation.

Additionally, Tc99m tilmanocept uptake in RA-inflamed joints helped clinicians differentiate patients with the fibroid pathotype with low macrophage involvement from those having pathotypes of RA with higher macrophage involvement, the company said.

The primary objective of the study is to assess the relationship between joint-specific Tc-99m tilmanocept uptake values and the pathobiology of RA-involved joint tissue.

Copyright © 2022

To read this and get access to all of the exclusive content on create a free account or sign-in now.

Member Sign In:
MemberID or Email Address:  
Do you have a password?
No, I want a free membership.
Yes, I have a password:  
Forgot your password?
Sign in using your social networking account:
Sign in using your social networking